Corvus Pharmaceuticals (NASDAQ:CRVS) Lowered to “Sell” Rating by Wall Street Zen

Corvus Pharmaceuticals (NASDAQ:CRVS) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Other analysts have also recently issued reports about the company. HC Wainwright boosted their price objective on Corvus Pharmaceuticals from $11.00 to $27.00 and gave the company a “buy” rating in a research report on Tuesday, January 20th. Barclays increased their target price on Corvus Pharmaceuticals from $16.00 to $28.00 and gave the company an “overweight” rating in a research report on Tuesday, January 20th. Jefferies Financial Group lifted their price target on shares of Corvus Pharmaceuticals from $13.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. Oppenheimer restated an “outperform” rating and set a $33.00 price objective (up from $32.00) on shares of Corvus Pharmaceuticals in a research report on Friday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Corvus Pharmaceuticals in a report on Friday. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Corvus Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $32.00.

Corvus Pharmaceuticals Stock Down 4.3%

CRVS stock opened at $15.32 on Friday. Corvus Pharmaceuticals has a 52-week low of $2.54 and a 52-week high of $26.95. The firm has a market cap of $1.28 billion, a P/E ratio of -30.64 and a beta of 0.78. The company’s 50-day simple moving average is $16.46 and its 200-day simple moving average is $10.53.

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.01). On average, analysts anticipate that Corvus Pharmaceuticals will post -0.63 earnings per share for the current fiscal year.

Institutional Trading of Corvus Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. lifted its stake in Corvus Pharmaceuticals by 26.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,629 shares of the company’s stock worth $28,000 after purchasing an additional 748 shares in the last quarter. ProShare Advisors LLC boosted its holdings in Corvus Pharmaceuticals by 7.7% in the 4th quarter. ProShare Advisors LLC now owns 13,764 shares of the company’s stock valued at $106,000 after purchasing an additional 979 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Corvus Pharmaceuticals by 5.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 34,105 shares of the company’s stock valued at $263,000 after purchasing an additional 1,696 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Corvus Pharmaceuticals by 6.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 32,232 shares of the company’s stock valued at $238,000 after buying an additional 1,812 shares during the period. Finally, Shelton Wealth Management LLC grew its stake in shares of Corvus Pharmaceuticals by 13.8% in the 4th quarter. Shelton Wealth Management LLC now owns 15,638 shares of the company’s stock valued at $120,000 after buying an additional 1,896 shares during the period. Institutional investors and hedge funds own 46.64% of the company’s stock.

More Corvus Pharmaceuticals News

Here are the key news stories impacting Corvus Pharmaceuticals this week:

• Positive Sentiment: Oppenheimer reaffirmed an “outperform” rating and raised its price target to $33 (from $32), implying substantial upside from current levels — a clear analyst vote of confidence that can support longer‑term buying interest. Oppenheimer Rating/Price Target
• Positive Sentiment: Company announced positive safety and efficacy data from cohort 4 of soquelitinib in a Phase 1 atopic dermatitis trial, including responses in patients with prior systemic therapy — this clinical progress materially de‑risks the program and supports future value for the pipeline. Atopic Dermatitis Trial Data
• Neutral Sentiment: Corvus released its Q4 2025 results and held an earnings call; management highlighted strategic advances tied to the pipeline and provided a business update, but the call materials are a mixed read for near‑term revenue prospects. Earnings Call Highlights
• Negative Sentiment: Q4 EPS came in at ($0.15), missing consensus by $0.01 — a small miss but enough to pressure sentiment in the absence of immediate revenue drivers; this likely contributed to the intraday pullback. Earnings Miss / Transcript
• Neutral Sentiment: Reported short‑interest updates in recent days show anomalous/zero values and appear unreliable — there is no clear evidence of a near‑term short squeeze or meaningful short pressure based on the published figures. (No actionable link available.)

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.